Main news


Weight Loss During Heart Failure Hospitalization Linked to Lower 30-Day Rehospitalization Risk Patients hospitalized for heart failure who were treated with intravenous loop diuretics and achieved a weight loss of at least 2 kg between admission and discharge had a reduced risk for HF rehospitalization within 30 days.



Allergic vasospastic angina: a systematic review Allergic vasospastic angina (also known as Kunis syndrome) is a little‑studied subtype of vasospastic angina in which spasm of the coronary arteries is triggered by an allergen. Scientists conducted a study in which they assessed the clinical characteristics, mechanisms, and treatment methods for this interesting subtype of angina.



Fitness Changes Over Time Linked to Cardiovascular Risk A large UK Biobank analysis showed that even a small annual improvement in cardiorespiratory fitness among adults was independently associated with lower risks for incident cardiovascular disease and cardiovascular mortality, whereas declining fitness was linked to a progressively higher risk in a clear dose-dependent pattern.



Cardioprotection Rarely Used in Adults With Blood Cancers In a US cohort study of adults on anthracycline-based therapy for hematologic cancers, only 1%-2% received strategies to lower the risk for treatment-related heart damage.



New horizons of cardiotherapy Since the introduction of the first implantable stimulator and defibrillator (ICD), cardiological science has advanced far. ICDs are highly effective, but their main disadvantage is the complications associated with the electrodes. To avoid the need for venous access and complications caused by transvenous electrodes, a fully subcutaneous ICD system (pc-ICD) was developed.



Integrated model of medical care for the treatment of ST-segment elevation myocardial infarction in China A new study involving 6817 patients with acute ST-segment elevation myocardial infarction has shown that every minute of life counts. Chinese scientists have tested an integrated aid model. This study assessed the impact of a comprehensive IMPST treatment strategy in China.



The relationship between low‑density lipoprotein cholesterol, the apolipoprotein B ratio, and sarcopenia The ratio of low‑density lipoprotein cholesterol to apolipoprotein B (LDL‑C/ApoB) (LDL-C/ApoB), which reflects the cholesterol content in an atherogenic lipoprotein particle, may serve as a new biomarker for the risk of sarcopenia. Scientists conducted a study based on data from the largest American representative survey (NHANES).



Blood Pressure Variability Linked to Cognitive Decline in High-Risk Adults Higher visit-to-visit systolic blood pressure variability was independently associated with faster cognitive decline in adults at elevated cardiovascular risk, regardless of mean blood pressure levels in a study.



General Anesthesia Ups Heart Failure Risk After Valve Surgery Transcatheter aortic valve replacement (TAVR) patients who received general anesthesia had a higher incidence of heart failure at 1 year than those who received nongeneral anesthesia.



ACE inhibitors may slow cognitive decline Patients treated exclusively with angiotensin-converting enzyme inhibitors had lower overall cancer incidence than those treated exclusively with angiotensin receptor blockers over 23 years of follow-up. ACEI therapy was linked to lower odds for breast, prostate, melanoma, non-Hodgkin lymphoma, kidney, and colorectal cancers, but higher odds for lung, bladder, and pancreatic cancers.


Most important clinical trials presented at the HOT LINE sessions of the European Society of Cardiology Congress 2026
Most important clinical trials presented at the HOT LINE sessions of the European Society of Cardiology Congress 2026 The next Congress of the European Society of Cardiology was held in Munich (Germany) from August 28 to 31, 2026. The motto of this year's event is "Research. Innovation. Inspiration." The Congress participants reviewed 4 new texts of clinical recommendations in various fields of cardiology and other fields of medicine.


ACC and AHA updated their recommendations on statins in 2026
ACC and AHA updated their recommendations on statins in 2026 Cardiologists have revised the 2018 statin recommendations. After just under 10 years, during which the target indicators were based solely on percentage reduction, clear numerical target levels for low‑density lipoproteins have been re‑established.


Editorial Activity

cardiology book

New Tool to Guide Transcatheter Aortic Valve Replacement
New Tool to Guide Transcatheter Aortic Valve Replacement A new German trigger tool identified adverse events in pediatric cardiology admissions, with most events causing temporary harm. The tool demonstrated good interrater reliability and was feasible for systematic detection of patient harm in hospitalized children.


The release of a new open access journal of cardiology
The release of a new open access journal of cardiology In August 2026, a group of cardiologists launched the peer—reviewed open access journal OpenSource: Cardiology. The main difference of the publication is the complete absence of publication fees for the authors.


To Beat Cigarette Addiction, Experts Embrace Vapes
To Beat Cigarette Addiction, Experts Embrace Vapes Clinicians can now recommend vapes, along with nicotine patches and gums, to their adult patients who want to quit smoking traditional cigarettes. The guidance, from a leading international group of tobacco researchers, represents a sharp pivot from an earlier stance that evolved as evidence mounted that vaping may be more effective in helping people quit cigarettes than traditional nicotine replacement therapies like varenicline or bupropion.


New Guidelines Expand Statin Eligibility to More Than Half of US Adults
New Guidelines Expand Statin Eligibility to More Than Half of US Adults A new study has shown that the updated recommendations of the American Heart Association and the American College of Cardiology on dyslipidemia, published in March 2026, expand indications for statin therapy for primary prevention, now covering adults aged 30-79 years (instead of 40-75 years), assessing the risk for several decades ahead and using an updated risk calculator, which will allow such treatment to spread. 87.5 million adults in the United States.


Obesity and CVD: Launching the Heart Foundation's new clinical consensus statement
Obesity and CVD: Launching the Heart Foundation's new clinical consensus statement In Australia, about two-thirds of adults are overweight or obese, placing them at increased risk of cardiovascular disease (CVD) including coronary heart disease, heart failure, and arrhythmias. The Heart Foundation recently launched an Australian-first clinical consensus statement on obesity and CVD.


Simulation deficit in cardiology training: a missed opportunity for the modern trainee
Simulation deficit in cardiology training: a missed opportunity for the modern trainee Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning.


Shingles vaccine protects against cardiovascular diseases
Shingles vaccine protects against cardiovascular diseases Shingles vaccination reduced major adverse cardiac events and secondary cardiovascular outcomes for patients with atherosclerotic cardiovascular disease, according to new research.


Heart failure evidence update 2026
Heart failure evidence update 2026 The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction spectrum.